The 3rd Antibody-Drug Conjugate (ADC) in Boston, MA, brought together a group of diverse yet deeply specialized experts who shared their knowledge, clinical insights, and technical experience with remarkable openness and clarity. The focus of the summit was on toxicities associated with Antibody-Drug Conjugates, a class of targeted cancer therapies that have shown great promise but also present challenges — especially in terms of off-target effects and patient safety.
Sonia Jain (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: